Patents by Inventor Robert B. DuBridge

Robert B. DuBridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20200347132
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
    Type: Application
    Filed: March 5, 2020
    Publication date: November 5, 2020
    Inventors: Chad MAY, Robert B. DUBRIDGE, Maia VINOGRADOVA, Anand PANCHAL
  • MESOTHELIN BINDING PROTEINS
    Publication number: 20200289646
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: September 17, 2020
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • MSLN TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE
    Publication number: 20200270362
    Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • MSLN targeting trispecific proteins and methods of use
    Patent number: 10730954
    Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 4, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20200231672
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • Mesothelin binding proteins
    Patent number: 10543271
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 28, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Single chain variable fragment CD3 binding proteins
    Patent number: 10544221
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 28, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
    Publication number: 20190076524
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Inventors: Chad MAY, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20190031749
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: October 16, 2018
    Publication date: January 31, 2019
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • MSLN TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE
    Publication number: 20180327508
    Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • MESOTHELIN BINDING PROTEINS
    Publication number: 20180326060
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 15, 2018
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • Single domain serum albumin binding protein
    Patent number: 10100106
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 16, 2018
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • Single chain variable fragment CD3 binding proteins
    Patent number: 10066016
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 4, 2018
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • PSMA Targeting Trispecific Proteins and Methods of Use
    Publication number: 20180162949
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • INDUCIBLE BINDING PROTEINS AND METHODS OF USE
    Publication number: 20180134789
    Abstract: Provided herein are conditionally activated polypeptide constructs comprising a protease-activated domain binding to CD3, at least one half-life extension domain, and two or more domains binding to one or more target antigens. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such polypeptide constructs. Also disclosed are methods of using the disclosed polypeptide constructs in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 6, 2017
    Publication date: May 17, 2018
    Inventors: Patrick BAEUERLE, Robert B. DUBRIDGE, Holger WESCHE, Luke EVNIN, Jeanmarie GUENOT, Anand PANCHAL, Maia VINOGRADOVA
  • Single domain serum albumin binding protein
    Patent number: 9920115
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: March 20, 2018
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20170369575
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20170369563
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20170334979
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20170334997
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON